CureDRPLA hosted an in-person research conference in Boston on October 10-11, with 26 attendees. Including researchers from academic institutions in the US, UK, Italy and Japan attended the conference, along with representatives from Vico Therapeutics B.V, Alnylam...
CureDRPLA is currently funding a Natural History and Biomarkers Study, aimed at gaining a deeper understanding of the progression of DRPLA over time, as well as identifying any genetic factors and markers that might predict disease progression. This study will provide...
It is time we created a space for our funded researchers to shine and acknowledge publicly their tremendous contributions to the field. This will be an ongoing feature in which we will introduce all our funded researchers from around the world to our readers. The...
CureDRPLA was a proud exhibitor at the International Congress of Parkinson's Disease and Movement Disorders in Copenhagen, held from August 27-31. This event drew in a remarkable crowd of over 5,200 in-person attendees representing more than 100 countries. This...
The FDA, the US regulatory agency for new medicines, declined to review the documents for a potential therapy for SCA3 (type of ataxia) developed by Biohaven. The criteria for approving a drug often rely on standards established for more prevalent conditions, making...